Investor Relations

News

Date Title and Summary Additional Formats
Toggle Summary CMS Approves SINUVA® Sinus Implant for Reimbursement with New C‐Code and Pass‐Through Payment Status
Toggle Summary FDA Performs Pre-Approval Inspection of Intersect ENT’s Menlo Park Facility
MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 6, 2017-- Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the U.S. Food and Drug Administration ( FDA ) has performed a Pre-Approval Inspection
View HTML
Toggle Summary Groundbreaking Clinical Evidence Demonstrates Benefit of PROPEL Implant for Chronic Sinusitis Patients
Toggle Summary Intersect ENT Added to Russell 2000 Index
MENLO PARK, Calif., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Intersect ENT (Nasdaq:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today announced that the Company has been added to the Russell 2000 ® index, effective as of the close of
View HTML
Toggle Summary Intersect ENT Announces $65 Million Convertible Notes Investment from Deerfield Management
MENLO PARK, Calif. --(BUSINESS WIRE)--May 11, 2020-- Intersect ENT, Inc. (Nasdaq: XENT), a company transforming care for patients with ear, nose and throat (“ENT”) conditions, today announced that it has closed a $65 million convertible notes financing with a fund managed by Deerfield Management
View HTML
Toggle Summary Intersect ENT Announces a Pivotal Study Publication of PROPEL® Contour Steroid Releasing Sinus Implant
Study Builds on the Extensive Clinical Evidence for Steroid Releasing Sinus Implants MENLO PARK, Calif. --(BUSINESS WIRE)--Nov. 2, 2017-- Intersect ENT, Inc. (NASDAQ: XENT) today announced a pivotal study publication of the second cohort of the prospective, randomized, blinded, multi-center
View HTML
Toggle Summary Intersect ENT Announces American Rhinologic Society Endorsement of the Use of Drug Eluting Sinus Implants
Toggle Summary Intersect ENT Announces Appointment of Chief Financial Officer Jeryl Hilleman
Toggle Summary Intersect ENT Announces Appointment of Cynthia L. Lucchese to Board of Directors
Toggle Summary Intersect ENT Announces Appointment of New Chief Financial Officer